Home
Alumis, Inc.

Alumis, Inc. Market Share Analysis for August 2026

we are using a precision approach to develop therapies designed to transform the lives of patients with immune-mediated diseases.

Health > Biotechnology and Pharmaceuticals

Domainalumis.com

Year Founded2021

Employees51 - 200

Annual Revenue$15M - $25M

Alumis, Inc.

Alumis, Inc. (including company regionals)

alumis.com

See more website traffic and engagement information

Alumis, Inc. Revenue up to August 2026 is 15M - 25M

revenue generated by Alumis, Inc. top domains

Alumis, Inc. top domains revenue over 3 years

Revenue for Alumis, Inc. top domains

alumis.com15M - 25M

See more with Sales Intelligence

Total visits to Alumis, Inc.'s top domains

Understand Alumis, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

alumis.com17.5K

See more with Sales Intelligence

Avg. visit duration in Alumis, Inc.'s top domains

Analyze Alumis, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

alumis.com00:01:18

See more with Sales Intelligence

Avg. pageviews on Alumis, Inc.'s top domains

See how Alumis, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

alumis.com2.60

See more with Sales Intelligence

Alumis, Inc. top competitors by domain

Top similar sites in August 2026, ranked by their affinity

xencor.comCompany NameXencorEmployees201 - 500HQUnited States, California, MonroviaAnnual revenue$100M - $200MTotal visits8.4KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Alumis, Inc.

These are the website technologies, by industry, used by Alumis, Inc. top domains

Payment & Currencies (8)

Cart Functionality

Email Services (3)

G Suite

eCommerce (2)

Swap

Mobile (2)

Meta Viewport

More Technologies

10

See all

News & Signals from Alumis, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAlumis will develop pipeline of oral tyrosine kinase 2 inhibitors on Sep 15th '26.Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005, its central nervous system penetrant TYK2 inhibitor, with initial development focused on Parkinson's disease and additional neuroinflammatory, neurodegenerative and peripheral immune-mediated disease indications under evaluation.

NewsAlumis has revenue of $3.65M.* Alumis reported weaker-than-expected quarterly results, with a loss of $1.11 per share versus the $0.77 consensus estimate and revenue of $1.66 million versus expectations of $3.65 million.

NewsAlumis had revenue of $1.66M on Apr 1st '26.* Alumis shares rose 2.4% to $24.99, but the company reported weaker-than-expected quarterly results, including an EPS loss of $0.78 versus the $0.73 consensus estimate and revenue of $1.66 million versus $3.47 million expected.